HighTower Advisors
HRTX icon

HighTower Advisors’s Heron Therapeutics HRTX Stock Holding History

HighTower Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1K Buy
17,612
+816
+5% +$946 ﹤0.01% 3773
2025
Q4 		$21.8K Sell
16,796
-4,000
-19% -$4.94K ﹤0.01% 3610
2025
Q3 		$26.2K Hold
20,796
– – ﹤0.01% 3654
2025
Q2 		$43K Hold
20,796
– – ﹤0.01% 3559
2025
Q1 		$45.8K Buy
20,796
+4,568
+28% +$8.87K ﹤0.01% 3463
2024
Q4 		$24.8K Sell
16,228
-500
-3% -$810 ﹤0.01% 3527
2024
Q3 		$34K Buy
16,728
+4,199
+34% +$10K ﹤0.01% 3459
2024
Q2 		$45K Sell
12,529
-30,000
-71% -$92.2K ﹤0.01% 3321
2024
Q1 		$120K Sell
42,529
-30,032
-41% -$75.5K ﹤0.01% 3112
2023
Q4 		$122K Buy
72,561
+61,801
+574% +$68K ﹤0.01% 3152
2023
Q3 		$11K Buy
+10,760
New +$15.3K ﹤0.01% 3379
2020
Q3 		– Sell
-9,822
Closed -$145K – 2606
2020
Q2 		$145K Buy
+9,822
New +$161K ﹤0.01% 2061
2020
Q1 		– Sell
-12,362
Closed -$290K – 2351
2019
Q4 		$290K Buy
12,362
+457
+4% +$10.1K ﹤0.01% 1746
2019
Q3 		$223K Buy
11,905
+974
+9% +$17.9K ﹤0.01% 1998
2019
Q2 		$205K Sell
10,931
-4,396
-29% -$87.8K ﹤0.01% 2048
2019
Q1 		$373K Sell
15,327
-2,988
-16% -$78.2K ﹤0.01% 1615
2018
Q4 		$477K Buy
18,315
+62
+0.3% +$1.71K ﹤0.01% 1377
2018
Q3 		$576K Sell
18,253
-1,000
-5% -$37.2K ﹤0.01% 1393
2018
Q2 		$749K Sell
19,253
-951
-5% -$30.3K 0.01% 1260
2018
Q1 		$560K Sell
20,204
-8,675
-30% -$197K ﹤0.01% 1355
2017
Q4 		$522K Buy
28,879
+8,495
+42% +$139K ﹤0.01% 1428
2017
Q3 		$327K Buy
20,384
+3,800
+23% +$59.6K ﹤0.01% 1646
2017
Q2 		$231K Buy
16,584
+1,700
+11% +$24.6K ﹤0.01% 1775
2017
Q1 		$225K Hold
14,884
– – ﹤0.01% 1705
2016
Q4 		$196K Sell
14,884
-7,300
-33% -$115K ﹤0.01% 1687
2016
Q3 		$380K Buy
22,184
+4,280
+24% +$79.4K ﹤0.01% 1360
2016
Q2 		$322K Buy
17,904
+37
+0.2% +$722 ﹤0.01% 1295
2016
Q1 		$340K Sell
17,867
-2,750
-13% -$54.3K ﹤0.01% 1559
2015
Q4 		$550K Sell
20,617
-5,094
-20% -$136K 0.01% 1267
2015
Q3 		$627K Buy
25,711
+16,443
+177% +$548K 0.01% 1109
2015
Q2 		$289K Buy
+9,268
New +$174K ﹤0.01% 1210

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

HighTower Advisors's HRTX Position: Q1 2026 in Review

HighTower Advisors increased its Heron Therapeutics (HRTX) stake by 4.9% in Q1 2026, buying an estimated $946 and bringing the position to 17,612 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3773.

HighTower Advisors first reported a position in HRTX in Q2 2015 and has held it in 31 quarters since. The position peaked at $749K in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • HighTower Advisors held 17,612 shares of Heron Therapeutics worth $14.1K as of Q1 2026.
  • HighTower Advisors bought 816 Heron Therapeutics shares in Q1 2026, an estimated $946.
  • Heron Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3773 holding.
  • HighTower Advisors first reported a position in Heron Therapeutics in Q2 2015 and has held it in 31 quarters since.
  • HighTower Advisors's Heron Therapeutics position peaked at $749K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.